Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FTO rs7195994 Is associated with TNF inhibitor response in lean rheumatoid arthritis patients: A BMI-stratified pharmacogenetic analysis.

The pharmacogenomics journal - 5 May 2026

Li Yi-Ting, Chen I-Chieh, Yang Hui-Wen, Kao Chung-Mao, Chen Yen-Ju, Huang Wen-Nan, Chen Yi-Ming

Abstract excerpt

Tumor necrosis factor inhibitors (TNFi) have transformed the management of rheumatoid arthritis (RA); however, up to 40% of patients fail to achieve an adequate clinical response. Current clinical predictors remain insufficient, highlighting the need for pharmacogenetic biomarkers to guide biologic therapy selection. In this study, we investigated genetic variants associated with TNFi treatment response, with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alpha-Ketoglutarate-Dependent Dioxygenase FTO
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis, Rheumatoid

Share to Body Mass Index

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Thinness

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 42086550
DOI: 10.1038/s41397-026-00409-1
PMCID: PMC13143807

Genes

FTO
ZNF618
CD84
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FTO rs7195994 Is associated with TNF inhibitor response in lean rheumatoid arthritis patients: A BMI-stratified pharmacogenetic analysis.PMID 42086550Read ↗

Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.Semantic proximity Read ↗

Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.Semantic proximity Read ↗

Genetic and Genomic Markers of Anti-TNF Treatment Response in Rheumatoid ArthritisSemantic proximity Read ↗

Association of RETN and TNFRSF1B polymorphisms with TNF-α inhibitor response in rheumatoid arthritis patientsSemantic proximity Read ↗

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisSemantic proximity Read ↗

Identification of a novel transcriptome signature for predicting the response to anti-TNF-α treatment in rheumatoid arthritis patientsSemantic proximity Read ↗

Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?Semantic proximity Read ↗

Genetic variants in the TNF pathway impact TNFi response in a mixed population with rheumatoid arthritis.Semantic proximity Read ↗

Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directionsSemantic proximity Read ↗

Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis.Semantic proximity Read ↗

Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.